Dynamics of circulating VEGF-A predict benefit from anti-angiogenic cediranib in metastatic or recurrent cervical cancer patients
Zhou, Cong Taylor, S Tugwood, Jonathan D Simpson, Kathryn L Jayson, Gordon C Symonds, P Paul, J Davidson, Susan E Carty, K McCartney, E
Zhou, Cong
Taylor, S
Tugwood, Jonathan D
Simpson, Kathryn L
Jayson, Gordon C
Symonds, P
Paul, J
Davidson, Susan E
Carty, K
McCartney, E
Citations
Altmetric:
Abstract
BACKGROUND AND PURPOSE:
There is a need for predictive and surrogate response biomarkers to support treatment with anti-angiogenic VEGF inhibitors. We aimed to identify a minimally-invasive biomarker predicting benefit from cediranib pre-treatment or early during treatment in patients with recurrent or metastatic cervical cancer.
EXPERIMENTAL APPROACH:
Blood samples were collected before treatment, during treatment and upon disease progression where appropriate from patients enrolled in CIRCCa, a randomised phase II trial of carboplatin and paclitaxel with or without cediranib. Plasma concentrations of VEGF-A, VEGF-R2, Ang1 and Tie2 were measured using multiplex ELISA. Pre-treatment and temporal changes of the biomarkers were investigated using proportional hazard regression and unsupervised clustering analysis.
KEY RESULTS:
Samples (n=556) from 52 patients were analysed. VEGF-R2 (p=0.0006) and Tie2 (p=0.04) were down-regulated following cediranib, while VEGF-A (p=0.0025) was up-regulated. High ECOG performance status (p=0.02, HR=2.15, 95%CI 1.13-4.09) and low pre-treatment Tie2 concentrations (p=0.003, HR= 0.57, 95%CI 0.39-0.83) were independent prognostic factors associated with reduced progression-free survival. Two patterns of changes in VEGF-A following cediranib were identified. Patients with elevated VEGA-A in the first 3 treatment cycles, regardless of magnitude, had reduced progression-free survival in the placebo arm but improved survival with the addition of cediranib (p=0.019, HR= 0.13, 95% CI 0.02-0.71).
CONCLUSIONS AND IMPLICATIONS:
Patterns of early elevation in plasma VEGF-A should be studied further as a potential biomarker to predict treatment benefit from cediranib.
Description
Date
2019
Publisher
Collections
Keywords
Type
Article
Citation
Zhou C, Taylor S, Tugwood J, Simpson K, Jayson GC, Symonds P, et al. Dynamics of circulating VEGF-A predict benefit from anti-angiogenic cediranib in metastatic or recurrent cervical cancer patients. Br J Clin Pharmacol. 2019.